PLX Berita Forex

Chiesi, Protalix Receive Positive CHMP Opinion For Pegunigalsidase Alfa To Treat Fabry Disease

Chiesi, Protalix Receive Positive CHMP Opinion For Pegunigalsidase Alfa To Treat Fabry Disease

Protalix BioTherapeutics, Inc. (PLX) and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending marketing authorization for PRX-102 (pegunigalsidase alfa), the first and only pegylated enzyme for the treatment of adult patients with Fabry disease.
RTTNews | 703 hari yang lalu